硼替佐米联合地塞米松对多发性骨髓瘤的疗效

[Effect of Velcade combined with Dexamethasone on multiple myeloma].

作者信息

He Qun, Zhao Xielan, He Yanjuan, Tan Daren

机构信息

Department of Hematology, Xiangya Hospital, Central South University, Changsha 410008, China.

出版信息

Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2010 Aug;35(8):864-7. doi: 10.3969/j.issn.1672-7347.2010.08.015.

DOI:10.3969/j.issn.1672-7347.2010.08.015

PMID:20818081

Abstract

OBJECTIVE

To compare the effect and safety between Velcade-Dexamethasone (VD)and revised Vinorebine+Pirarubicin+ Dexamethasone (VAD) regiment for multiple myeloma (MM).

METHODS

Thirty-six patients with MM were reviewed, 16 of whom were treated with VD (VD Group) and the others with VAD. European Group for Blood and Marrow Transplant (EBMT) criteria and National Cancer Institute Common Terminology Criteria for Adverse Events (NCICTCAE) were chosen to analyze the efficacy and side effects.

RESULTS

In the VD group and the revised VAD group, the rates of complete response, partial response, minimal response, no change and progress disease were 50% vs. 5%, 25% vs. 25%, 18.8% vs. 15%, 6.2% vs. 35% and 0 vs. 20%, respectively. The total response rates were 93.8% vs 45%. There was significant difference in the overall response rate between the 2 groups (P<0.05). The side effects were less serious, and the endurance was better in the VD group than those in the revised VAD group. No serious effects of hematology and cardiology were seen, and good endurance was showed in the renal dysfunction in the VD group.

CONCLUSION

Velcade combined with dexamethasone is a safe and effective regiment for multiple myeloma with good safety and endurance.

摘要

目的

比较万珂-地塞米松（VD）方案与改良长春瑞滨+吡柔比星+地塞米松（VAD）方案治疗多发性骨髓瘤（MM）的疗效及安全性。

方法

回顾性分析36例MM患者，其中16例接受VD方案治疗（VD组），其余患者接受VAD方案治疗。采用欧洲血液和骨髓移植组（EBMT）标准及美国国立癌症研究所不良事件通用术语标准（NCICTCAE）分析疗效及副作用。

结果

VD组与改良VAD组的完全缓解率、部分缓解率、最小缓解率、病情无变化率及疾病进展率分别为：50%对5%、25%对25%、18.8%对15%、6.2%对35%、0对20%。总缓解率分别为93.8%和45%。两组总缓解率差异有统计学意义（P<0.05）。VD组副作用较轻，耐受性优于改良VAD组。未观察到严重的血液学及心脏方面的不良反应，VD组肾功能耐受性良好。